Recent Articles

May 22, 2017 8:00 am
Meg LaTorre-Snyder
“The industry-wide shift from volume- to value-based payment models and the move towards more personalized health care have helped fuel interest in using RWE to understand and demonstrate the value of pharmaceutical and medical device innovations,” Deloitte Consulting said in their RWE study.
May 17, 2017 8:03 am
Mike Botta
One big concern continues to center around a shortage of manufacturers even as demand increases.
May 15, 2017 8:30 am
Sean Riley, Senior Director, Media and Industry Communications, PMMI
Biosimilars have the same clinical effect as a generic but are only as similar to the original branded drug as validation technologies can confirm.
May 12, 2017 8:00 am
Joseph P. Szcza, Director of Operations and Michel Thénin, General Manager, Fluid Air
The electrostatic spray drying technology uses an atomizing nozzle where a charge is applied to the feedstock during atomization.
May 11, 2017 8:00 am
Meg LaTorre-Snyder
Two of today’s emerging markets in the pharmaceutical space, China and Ireland, continue to make a mark on the global market as a whole, while operating independently and excelling in diverse areas.
May 10, 2017 1:15 pm
Mike Botta
Despite immense challenges and hurdles, biosimilars may be where generic medicines were in the mid-1980s.
May 10, 2017 1:10 pm
Walt Murray, President and CEO, ARC Experts
The tracking systems resulting from DSCSA will complement the drug design control process, which includes guidelines that companies must follow in order to enter ingredients into the supply chain.
May 10, 2017 1:05 pm
Mike Botta
Leveraging tech transfer and analytical capabilities to enter new markets and absorbing additional production steps that brand owners are seeking to offload.
May 10, 2017 1:00 pm
Meg LaTorre-Snyder
CMO Symbiosis Pharmaceutical Services, a small-scale, niche sterile manufacturer, finds market sweet spot in the development and manufacturing of biologics, highly potent APIs, and small molecules.
May 10, 2017 1:20 pm
Mike Botta
India-based Dr. Reddy's expects the bulk of short-term market growth to be in complex generics, while mid- to long-term likely will shift toward biosimilars.
Subscribe to Pharmaceutical Processing